Zumla, A. et al. Coronaviruses—drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327–347 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng, V. C. et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20, 660–694 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465–522 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

To, K. K. et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg. Microbes Infect. 10, 507–535 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeon, S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 64, e00819-20 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Yuan, S. et al. Broad-spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19). Viruses 12, 628 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113–119 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jang, W. D. et al. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc. Natl Acad. Sci. USA 118, e2024302118 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luttens, A. et al. Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J. Am. Chem. Soc. 144, 2905–2920 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gunther, S. et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 372, 642–646 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289–293 (2020).

Article  CAS  PubMed  Google Scholar 

Chen, C. Z. et al. Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2. Front. Pharmacol. 11, 592737 (2020).

Article  CAS  PubMed  Google Scholar 

Yuan, S. et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol. Res. 159, 104960 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hung, I. F. et al. Triple combination of interferon β-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695–1704 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 382, 1787–1799 (2020).

Article  PubMed  Google Scholar 

Beigel, J. H. et al. Remdesivir for the treatment of COVID-19—final report. N. Engl. J. Med. 383, 1813–1826 (2020).

Article  CAS  PubMed  Google Scholar 

Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56, 105949 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 — interim WHO Solidarity Trial results. N. Engl. J. Med. 384, 497–511 (2021).

Article  Google Scholar 

Cihlar, T. & Mackman, R. L. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 27, 13596535221082773 (2022).

Article  PubMed  Google Scholar 

Masyeni, S. et al. Molnupiravir: a lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—a narrative review. J. Med. Virol. 94, 3006–3016 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Food & Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. US Food & Drug Administration https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 (2020).

Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586–1593 (2021).

Article  CAS  PubMed  Google Scholar 

Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451–457 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valero, J. et al. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proc. Natl Acad. Sci. USA 118, e2112942118 (2021).

Article  PubMed  PubMed Central  Google Scholar 

de Vries, R. D. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 371, 1379–1382 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).

Article  CAS  PubMed  Google Scholar 

Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553–556 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, L. et al. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Sci. Transl. Med. 14, eabn6859 (2022).

Article  CAS  PubMed  Google Scholar 

Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103–108 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiang, Y. et al. Superimmunity by pan-sarbecovirus nanobodies. Cell Rep. 39, 111004 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia, S. et al. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 32, 404–406 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, H. et al. Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. Emerg. Microbes Infect. 11, 926–937 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan, S. et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell 13, 940–953 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quan, B. X. et al. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including